{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:32:50Z","timestamp":1791405170750,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"am","delay-in-days":312,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010874","name":"American Society for Bone and Mineral Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016289","name":"Taiju Life Social Welfare Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016399","name":"Japan Osteoporosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bone.2022.116605","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T12:51:20Z","timestamp":1667652680000},"page":"116605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan"],"prefix":"10.1016","volume":"166","author":[{"given":"Masayuki","family":"Iki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Nakatoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniyasu","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumito","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2022.116605_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","article-title":"Bone loss in response to long-term glucocorticoid therapy","volume":"8","author":"LoCascio","year":"1990","journal-title":"Bone Miner."},{"issue":"10","key":"10.1016\/j.bone.2022.116605_bb0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-119-10-199311150-00001","article-title":"Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study","volume":"119","author":"Laan","year":"1993","journal-title":"Ann. Internal Medicine"},{"issue":"4","key":"10.1016\/j.bone.2022.116605_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","article-title":"Oral glucocorticoid use is associated with an increased risk of fracture","volume":"15","author":"Steinbuch","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2022.116605_bb0020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2022.116605_bb0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos. Int."},{"issue":"7","key":"10.1016\/j.bone.2022.116605_bb0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporos. Int."},{"issue":"7","key":"10.1016\/j.bone.2022.116605_bb0035","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.injury.2016.04.018","article-title":"Quality of life after hip fracture in the elderly: a systematic literature review","volume":"47","author":"Peeters","year":"2016","journal-title":"Injury"},{"issue":"26","key":"10.1016\/j.bone.2022.116605_bb0040","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"Buckley","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bone.2022.116605_bb0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2022.116605_bb0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.11005\/jbm.2020.27.4.247","article-title":"Intervention thresholds for treatment in patients with glucocorticoid-induced osteoporosis: systematic review of guidelines","volume":"27","author":"Lee","year":"2020","journal-title":"J. Bone Metab."},{"issue":"8","key":"10.1016\/j.bone.2022.116605_bb0055","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.bone.2022.116605_bb0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the japanese Society for Bone and Mineral Research: 2014 update","volume":"32","author":"Suzuki","year":"2014","journal-title":"J. Bone Miner. Metab."},{"issue":"10","key":"10.1016\/j.bone.2022.116605_bb0065","article-title":"Bisphosphonates for steroid-induced osteoporosis","volume":"10","author":"Allen","year":"2016","journal-title":"Cochrane Database Syst. Reviews"},{"issue":"12","key":"10.1016\/j.bone.2022.116605_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080890","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One"},{"issue":"42","key":"10.1016\/j.bone.2022.116605_bb0075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012691","article-title":"Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: a meta-analysis of randomized controlled trials","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.bone.2022.116605_bb0080","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00198-015-3476-4","article-title":"Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis","volume":"27","author":"Amiche","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2022.116605_bb0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3318","article-title":"Effectiveness of Oral bisphosphonates in reducing fracture risk among Oral glucocorticoid users: three matched cohort analyses","volume":"33","author":"Amiche","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2022.116605_bb0090","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2017.8040","article-title":"Association between alendronate use and hip fracture risk in older patients using Oral prednisolone","volume":"318","author":"Axelsson","year":"2017","journal-title":"JAMA"},{"issue":"3\u20134","key":"10.1016\/j.bone.2022.116605_bb0095","first-page":"55","article-title":"The claim database in Japan","volume":"6","author":"Matsuda","year":"2012","journal-title":"Asian Pac. J. Dis. Manag."},{"key":"10.1016\/j.bone.2022.116605_bb0100","author":"Japanese Ministry of Health, Labour and Welfare"},{"key":"10.1016\/j.bone.2022.116605_bb0105","author":"Japanese Ministry of Health, Labour and Welfare"},{"issue":"1","key":"10.1016\/j.bone.2022.116605_bb0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin. Immunol."},{"issue":"3","key":"10.1016\/j.bone.2022.116605_bb0115","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jclinepi.2012.10.004","article-title":"The validity of administrative data to identify hip fractures is high\u2013a systematic review","volume":"66","author":"Hudson","year":"2013","journal-title":"J. Clin. Epidemiol."},{"issue":"17","key":"10.1016\/j.bone.2022.116605_bb0120","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"issue":"2014","key":"10.1016\/j.bone.2022.116605_bb0125","article-title":"Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men","volume":"4","author":"Avenell","year":"2014","journal-title":"Cochrane Database Syst. Reviews"},{"issue":"20","key":"10.1016\/j.bone.2022.116605_bb0130","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bone.2022.116605_bb0135","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.bone.2022.116605_bb0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.3877","article-title":"Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition","volume":"35","author":"Conley","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116605_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116396","article-title":"Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: a nationwide health insurance claims database study in Japan","volume":"160","author":"Iki","year":"2022","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2022.116605_bb0150","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00198-021-06265-y","article-title":"Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study","volume":"33","author":"Iki","year":"2022","journal-title":"Osteoporos. Int."},{"issue":"20","key":"10.1016\/j.bone.2022.116605_bb0155","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.298.20.2381","article-title":"High-trauma fractures and low bone mineral density in older women and men","volume":"298","author":"Mackey","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bone.2022.116605_bb0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985\u20131989","volume":"7","author":"Cooper","year":"1992","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2022.116605_bb0170","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-007-0466-1","article-title":"Loss of treatment benefit due to low compliance with bisphosphonate therapy","volume":"19","author":"Penning-van Beest","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bone.2022.116605_bb0175","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1185\/030079906X132370","article-title":"Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study","volume":"22","author":"van den Boogaard","year":"2006","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222002824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222002824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:03:35Z","timestamp":1757613815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328222002824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"alternative-id":["S8756328222002824"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116605","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116605"}}